GlaxoSmithKline Plc's (GSK.L) new breast cancer pill Tykerb will receive a priority review from U.S. regulators in a move that should speed its path onto the world's biggest drugs market, it said on Thursday.
» Search Healthcare-Specific Tags: Tykerb - Breast Cancer Drug - GlaxoSmithKline
» Wires


Comments